Angeles Investment Advisors LLC Acquires 400 Shares of Johnson & Johnson (NYSE:JNJ)

Angeles Investment Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 6.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,197 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,004,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in JNJ. China Universal Asset Management Co. Ltd. bought a new stake in Johnson & Johnson in the 1st quarter worth about $765,000. Empowered Funds LLC boosted its position in Johnson & Johnson by 46.7% in the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock worth $16,015,000 after purchasing an additional 32,244 shares during the last quarter. O Dell Group LLC increased its position in shares of Johnson & Johnson by 8.6% during the 1st quarter. O Dell Group LLC now owns 3,472 shares of the company’s stock valued at $549,000 after purchasing an additional 276 shares during the last quarter. QRG Capital Management Inc. raised its stake in shares of Johnson & Johnson by 9.4% during the 1st quarter. QRG Capital Management Inc. now owns 453,858 shares of the company’s stock worth $71,796,000 after purchasing an additional 38,961 shares during the period. Finally, Qsemble Capital Management LP grew its position in Johnson & Johnson by 275.0% during the first quarter. Qsemble Capital Management LP now owns 19,221 shares of the company’s stock valued at $3,041,000 after buying an additional 14,096 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.4 %

Johnson & Johnson stock opened at $153.28 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a market cap of $369.04 billion, a P/E ratio of 22.18, a PEG ratio of 2.71 and a beta of 0.53. The firm’s 50 day moving average price is $162.10 and its 200-day moving average price is $156.01. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the firm posted $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on JNJ. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.